Biologic Therapy Program
The Biologic Therapy Program focuses on the treatment of advanced melanoma and kidney cancer. Our Biologic Therapy Program specialists, including Drs.David McDermott, James Mier and Rupal Bhatt, investigate and use biologic agents, such as cytokines and vaccines, to treat patients with advanced melanoma and kidney cancer.
Their pivotal efforts have helped develop standard approaches to these cancers. Clinicians see 200 new patients a year, offer more than 20 open research protocols, and enroll 150 plus patients annually in research studies. Specialized areas of research and treatment include:
- Interleukin-2 based therapy
- Vaccines, cytokines and other immunotherapies
- Angiogenesis and signal transduction inhibitors
- Pro-apoptotic agents to promote programmed cell death
Research study grants from NIH, foundations and industry support this groundbreaking work, as do two National Cancer Institute (NCI)-sponsored SPORE grants in skin and kidney cancer as a member of the Dana-Farber/Harvard Cancer Center (DF/HCC).
Patients with melanoma and kidney cancer who require surgical care are treated in our Melanoma/Skin and Kidney Tumor programs.
Our Biologic Therapy Program is Internationally recognized for contributions to the biologic treatment of cancer using cytokines (IL-2,1 FN), targeted immunotherapy (CTLA4 and PD1 antibodies), vaccines and other novel agents.